Illumina (NSDQ:ILMN) and Loxo Oncology (NSDQ:LOXO) are teaming up to develop a multi-gene panel for broad tumor profiling. The two companies ultimately hope to sell a next-gen sequencing-based companion diagnostic that will boast a pan-cancer indication.
Illumina and Loxo plan to seek approval for a version of Illumina’s TruSight Tumor 170 test as a companion diagnostic for two of Loxo’s drugs; larotrectinib, which targets NRTK gene fusions, and Loxo-292, which targets RET gene alterations.
Get the full story at our sister site, Drug Delivery Business News.
The post Illumina, Loxo Oncology partner for next-gen pan-cancer companion diagnostics appeared first on MassDevice.